Lapatinib Stada

Lapatinib, the active ingredient in Lapatinib Stada, is a tyrosine kinase inhibitor presented as a tablet for oral use. It selectively blocks HER2 and EGFR signaling pathways, thereby treating HER2‑positive metastatic breast cancer and HER2‑positive gastric cancer in adult patients who have progressed after prior therapy.\n\nGNH India supplies Lapatinib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide, with distribution across the European Union and other regulated markets, and reliable, efficient supply chains.

Lapatinib is a targeted therapy that inhibits HER2 and EGFR signaling pathways in cancers that overexpress these receptors.\n- HER2‑positive metastatic breast cancer: improves progression‑free survival when combined with chemotherapy in patients whose disease has progressed after prior HER2‑targeted therapy.\n- HER2‑positive gastric cancer: used with chemotherapy to extend disease control in patients with advanced disease.\n- HER2‑positive solid tumors in clinical trials: evaluated as part of combination regimens to assess efficacy in other HER2‑driven cancers.

Lapatinib may cause a range of adverse reactions, which are categorized by frequency and severity, and may require medical attention or dose adjustments.\nCommon Side Effects:\n- Diarrhea: frequent watery stools that may cause dehydration.\n- Nausea: feeling of sickness often accompanied by vomiting.\n- Rash: skin eruptions ranging from mild redness to pruritic lesions.\n- Fatigue: persistent tiredness affecting daily activities.\n- Hand-foot syndrome: redness,